Indication
Neonatal apnea
Neonatal apnea is a respiratory control disorder defined as an unexplained cessation of breathing lasting 20 seconds or longer, or a shorter pause accompanied by bradycardia, oxygen desaturation, or cyanosis in newborn infants. Read more about Neonatal apnea
19 drugs 13 manufacturers
Drugs that treat it
Common Neonatal apnea therapies.
CAFFEINE CITRATE
CAFCIT (caffeine citrate)
CAFFEINE CITRATE
CAFFEINE CITRATE
CAFFEINE CITRATE
CAFCIT (caffeine citrate)
CAFFEINE CITRATE
CAFFEINE CITRATE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonNeonatal apnea is a respiratory control disorder defined as an unexplained cessation of breathing lasting 20 seconds or longer, or a shorter pause accompanied by bradycardia, oxygen desaturation, or cyanosis in newborn infants.
Primarily affecting premature neonates as a manifestation of neurodevelopmental immaturity, it arises from blunted central chemoreceptor sensitivity and underdeveloped brainstem respiratory centers, though it may also be secondary to underlying systemic conditions such as sepsis, intracranial pathology, or metabolic disturbances.
Clinically, these episodes are classified as central, where neural respiratory drive is absent; obstructive, marked by pharyngeal collapse despite breathing effort; or mixed, which incorporates features of both mechanisms and represents the most common presentation in preterm infants.
- nih.gov
Neonatal apnea is a respiratory control disorder defined as an unexplained cessation of breathing lasting 20 seconds or longer, or a shorter pause accompanied by bradycardia, oxygen desaturation, or cyanosis in newborn infants Primarily affecting premature neonates as a manifestation of neurodevelopmental immaturity, it arises from blunted central chemoreceptor sensitivity and underdeveloped brainstem respiratory centers, though it may also be secondary to underlying systemic conditions such as ...
- mhmedical.com
Neonatal apnea is a respiratory control disorder defined as an unexplained cessation of breathing lasting 20 seconds or longer, or a shorter pause accompanied by bradycardia, oxygen desaturation, or cyanosis in newborn infants Clinically, these episodes are classified as central, where neural respiratory drive is absent; obstructive, marked by pharyngeal collapse despite breathing effort; or mixed, which incorporates features of both mechanisms and represents the most common presentation in pret...
- nih.gov
Primarily affecting premature neonates as a manifestation of neurodevelopmental immaturity, it arises from blunted central chemoreceptor sensitivity and underdeveloped brainstem respiratory centers, though it may also be secondary to underlying systemic conditions such as sepsis, intracranial pathology, or metabolic disturbances
- aap.org
Primarily affecting premature neonates as a manifestation of neurodevelopmental immaturity, it arises from blunted central chemoreceptor sensitivity and underdeveloped brainstem respiratory centers, though it may also be secondary to underlying systemic conditions such as sepsis, intracranial pathology, or metabolic disturbances
- newbornwhocc.org
Primarily affecting premature neonates as a manifestation of neurodevelopmental immaturity, it arises from blunted central chemoreceptor sensitivity and underdeveloped brainstem respiratory centers, though it may also be secondary to underlying systemic conditions such as sepsis, intracranial pathology, or metabolic disturbances
Personalize your experience
Follow Neonatal apnea and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.